Hepatitis C

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment [Phase 2]

  A Phase 2 trial (ANNAPURNA) evaluated the combination of RO5466731, RO5190591, Ritonavir, and Ribavirin with or without RO5024048 in patient…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy [Phase 1]

  Phase 1 study evaluating the pharmacokinetics and pharmacodynamics of intravenously administered Pegasys (peginterferon alfa-2a) in chronic …

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 [Phase 2]

  This Phase 2 study evaluated RO5024048 in combination with peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) in patients with chronic …

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1 [Phase 1]

  This Phase 1 study assesses safety, tolerability, and pharmacokinetics of RO5303253 in healthy volunteers and patients with chronic hepatiti…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C [Phase 1]

  Phase 1 study of the investigational compound RO5428029 investigated in healthy volunteers and chronic hepatitis C patients has completed.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 [Phase 2]

  A Phase 2 trial evaluating RO5024048 in combination with Pegasys (pegylated interferon alfa-2a) and Copegus (ribavirin) in treatment-naive p…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients [Phase 1]

  A Phase 1 study evaluated a combination of RO5024048 and RO5190591/Danoprevir in genotype 1 chronic hepatitis C patients; the trial has comp…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

  An observational study evaluating whether insulin resistance influences sustained virological response in patients with chronic hepatitis C …

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 [Phase 1]

  Phase 1 trial of ritonavir-boosted danoprevir with Pegasys and ribavirin for chronic hepatitis C genotype 1 has completed.

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection [Phase 2]

  A Phase 2 study evaluating danoprevir in combination with peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) for treatment-naive patien…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C [Phase 2]

  This Phase 2 clinical trial update reports completion of a study evaluating danoprevir/ritonavir and ribavirin with RO5024048 and/or Pegasys…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C [Phase 4]

  A Phase 4 trial evaluating the combination of Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in patients with chronic hepatitis C h…

• CLINICAL_TRIALS research · 2016-11-02
  Clinical Trial Update: An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection

  An observational study was conducted to assess liver fibrosis stages in patients with chronic hepatitis C infection. The study has completed…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1

  An observational study assessing whether rapid virological response predicts sustained virological response in treatment-naïve chronic hepat…

• CLINICAL_TRIALS withdrawal · 2016-11-02
  Clinical Trial Update: A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER) [Phase 3]

  A Phase 3 trial (MASTER) evaluating the safety of an individualized combination therapy with ribavirin (Copegus) and peginterferon alfa-2a (…

• CLINICAL_TRIALS trial_result · 2016-11-02
  Clinical Trial Update: An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

  This completed observational study (GUARD-C) looked at predicting adverse events in chronic hepatitis C patients treated with a long-acting …

• CLINICAL_TRIALS withdrawal · 2016-11-02
  Clinical Trial Update: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment [Phase 2]

  This Phase 2 trial update shows the study of RO5024048 in combination with ritonavir-boosted danoprevir and Pegasys/Copegus in chronic hepat…

• CLINICAL_TRIALS trial_result · 2016-11-01
  Clinical Trial Update: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. [Phase 4]

  This Phase 4 study evaluated peginterferon alfa-2a (PEGASYS) plus ribavirin in hemophiliac patients with chronic hepatitis C; the trial stat…

• CLINICAL_TRIALS research · 2016-11-01
  Clinical Trial Update: Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection. [Phase 4]

  Phase 4 efficacy trial evaluating new antiviral drugs for chronic hepatitis C. The current status of the trial is UNKNOWN.

• CLINICAL_TRIALS trial_result · 2016-10-31
  Clinical Trial Update: HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD) [Phase 3]

  Phase 3 trial update for peginterferon alfa-2a (Pegasys) in chronic hepatitis C patients, including those with end-stage renal disease, with…

• CLINICAL_TRIALS trial_result · 2016-10-27
  Clinical Trial Update: HCV Treatment in HIV Co-Infected Patients in Asia [Phase 4]

  This clinical trial update indicates a Phase 4 study evaluating Hepatitis C treatment in HIV co-infected patients in Asia has been completed…

• CLINICAL_TRIALS trial_result · 2016-10-26
  Clinical Trial Update: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection [Phase 3]

  Phase 3 trial comparing Sofosbuvir/velpatasvir fixed-dose combination for 12 weeks vs Sofosbuvir plus ribavirin for 24 weeks in adults with …

• CLINICAL_TRIALS trial_result · 2016-10-26
  Clinical Trial Update: Can Vitamin D Supplementation Improve Hepatitis C Cure Rates [Phase 3]

  This clinical trial update reports a Phase 3 study assessing whether adding Vitamin D supplementation can improve cure rates in people with …

• CLINICAL_TRIALS trial_result · 2016-10-25
  Clinical Trial Update: Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection [Phase 3]

  Phase 3 trial evaluating the safety and efficacy of sofosbuvir plus ribavirin in treatment-naive adults with chronic genotype 1 or genotype …

• CLINICAL_TRIALS trial_result · 2016-10-25
  Clinical Trial Update: Depression, Genes, Cytokines, Chronic Fatigue, Physical Illnesses and Quality of Life

  A completed clinical trial conducted by Chang Gung Memorial Hospital investigating the relationships among depression, genes, cytokines, chr…